AU2023215245A1 — Peptide inhibitors of interleukin-23 receptor and pharmaceutical compositions thereof
Assigned to Janssen Pharmaceutica NV · Expires 2024-09-19 · 2y expired
What this patent protects
The present invention relates to peptide inhibitor of the interleukin-23 receptor (IL-23R) or salts, solvates or forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation diseases and related disorders.
USPTO Abstract
The present invention relates to peptide inhibitor of the interleukin-23 receptor (IL-23R) or salts, solvates or forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation diseases and related disorders.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.